Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Chan, Lai N ^a   Fiji, Hannah D G ^a   Watanabe, Masaru ^a   Kwon, Ohyun ^a   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 225975; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; GERANYLGERANYLTRANSFERASE 1; GERANYLTRANSFERASE; P 61 A6; P 61 E7; P 61 EO7; P3 E5; PYRIDINE DERIVATIVE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; LEUCINE; PG1 E7 COMPOUND; PG1-E7 COMPOUND; PHOSPHINE; PHOSPHINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; TRANSFERASE;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CATALYSIS; CELL ANCHORAGE; CELL CYCLE PROGRESSION; CELL DISRUPTION; CELL LEVEL; CELL PROLIFERATION; CELL SHAPE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL CYCLE; CELL STRAIN 3T3; CHEMISTRY; CYTOSKELETON; CYTOSOL; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; FOCAL ADHESION; GENE EXPRESSION REGULATION; LEUKEMIA CELL LINE; METABOLISM; METHODOLOGY; MOUSE; PROTEIN PRENYLATION; PROTEIN TRANSPORT; SYNTHESIS;

ACTINS; ALKYL AND ARYL TRANSFERASES; ANIMALS; CATALYSIS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETON; CYTOSOL; DRUG DISCOVERY; ENZYME INHIBITORS; FOCAL ADHESIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; LEUCINE; MICE; NIH 3T3 CELLS; PHOSPHINES; PROTEIN PRENYLATION; PROTEIN TRANSPORT; PYRIDINES; PYRROLES; RHOA GTP-BINDING PROTEIN; SULFONAMIDES;

EID: 80054758429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026135     Document Type: Article

References (45)

1. Tamanoi F, Sigman DS, (2001) The Enzymes. Vol. 21. San Diego Academic Press.
2. Lim KH, Baines AT, Fiordalisi J, Shipitsin M, Feig LA, et al. (2005) Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7: 533-545.
3. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, et al. (2006) Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Current Biology 16: 2385-2394.
4. Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, et al. (2007) Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol 27: 8003-8014.
5. Clark EA, Golub TR, Lander ES, Hynes RO, (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
6. Harem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, et al. (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19: 1974-1979.
7. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, et al. (2007) GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 117: 1294-1304.
8. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, et al. (2004) Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23: 706-715.
9. Miquel K, Pradines J, Sun J, Qian Y, Hamilton AD, et al. (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57: 1846-1850.
10. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, et al. (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59: 4919-4926.
11. Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, et al. (2003) Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 63: 8922-8929.
12. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8: 1218-1226.
13. Sebti SM, Adjei AA, (2004) Farnesyltransferase Inhibitors. Semin Oncol 31: 28-39.
14. Lerner EC, Qian Y, Hamilton AD, Sebti SM, (1995) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270: 26770-26773.
15. Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, et al. (1999) Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem 42: 1333-1340.
16. Sun J, Qian Y, Hamilton AD, Sebti SM, (1998) Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16: 1467-1473.
17. Peterson YK, Kelly P, Weinbaum CA, Casey PJ, (2006) A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 281: 12445-12450.
18. Peterson YK, Wang XS, Casey PJ, Tropsha A, (2009) Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation. J Med Chem 52: 4210-20.
19. Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon P, et al. (2007) Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc 129: 5843-5845.
20. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283: 9571-9579.
21. Zhu X, Henry CE, Kwon O, (2005) Phosphine-catalyzed synthesis of 1,3-dioxan-4-ylidenes. Tetrahedron 61: 6276-6282.
22. Andrews IP, Kwon O, (2011) Phosphine Catalyzed [3+2] Annulation: Synthesis of Ethyl 5-(tert-Butyl)-2-phenyl-1-Tosyl-3-Pyrroline-3-Carboxylate. Org Synth 88: 138-151.
23. Zhu X-F, Lan J, Kwon O, (2003) An expedient phosphine-catalyzed [4 + 2] annulation: synthesis of highly functionalized tetrahydropyridines. J Am Chem Soc 125: 4716-4717.
24. Lu K, Kwon O, (2009) Phosphine-Catalyzed [4+2] Annulation: Synthesis of Ethyl 6-Phenyl-1-Tosyl-1,2,5,6-Tetrahydropyridine-3-Carboxylate. Org Synth 86: 212-224.
25. Guo H, Xu Q, Kwon O, (2009) Phosphine-promoted [3+3] annulations of aziridines with allenoates: facile entry into highly functionalized tetrahydropyridines. J Am Chem Soc 131: 6318-6319.
26. Zhu X, Henry CE, Wang J, Dudding T, Kwon O, (2005) Phosphine-catalyzed synthesis of 1,3-dioxan-4-ylidenes. Org Lett 7: 1387-1390.
27. Zhu X, Schaffner A, Li RC, Kwon O, (2005) Phosphine-catalyzed synthesis of 6-substituted 2-pyrones: manifestation of E/Z-isomerism in the zwitterionic intermediate. Org Lett 7: 2977-2980.
28. Creech GS, Kwon O, (2008) Alcohol-assisted phosphine catalysis: one-step syntheses of dihydropyrones from aldehydes and allenoates. Org Lett 10: 429-432.
29. Creech GS, Zhu X, Fonovic B, Dudding T, Kwon O, (2008) Theory-Guided Design of Bronsted Acid-Assisted Phosphine Catalysis: Synthesis of Dihydropyrones from Aldehydes and Allenoates. Tetrahedron 64: 6935-6942.
30. Tran YS, Kwon O, (2007) Phosphine-catalyzed [4+2] annulation: synthesis of cyclohexenes. J Am Chem Soc 129: 12632-12633.
31. Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L, et al. (2005) Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther 4: 918-26.
32. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, et al. (2002) Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 99: 14398-14403.
33. Sarma KD, Zhang J, Huang Y, Davidson JG, (2006) Amino Acid Esters and Amides for Reductive Amination of Mucochloric Acid: Synthesis of Novel γ-Lactams, Short Peptides and Antiseizure Agent Levetiracetam (Keppra®). Eur J Org Chem 2006: 3730-3737.
34. Wittchen ES, Aghajanian A, Burridge K, (2011) Isoform-specific differences between Rap1A and Rap1B GTPases in the formation of endothelial cell junctions. Small Gtpases 2: 65-76.
35. Terada K, Mori M, (2000) Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70. J Biol Chem 275: 24728-24734.
36. Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, et al. (2009) Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol 29: 2254-2263.
37. Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G, (2002) Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle 1: 430-437.
38. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM, (1998) p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 18: 6962-6970.
39. Olson MF, Paterson HF, Marshall CJ, (1998) Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 394: 295-299.
40. Allal C, Favre G, Couderc B, Salicio S, Sixou S, et al. (2000) RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275: 31001-31008.
41. Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, et al. (1999) The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J Biol Chem 274: 6930-6934.
42. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, et al. (1997) Geranylgeranylated Rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272: 13-16.
43. Hu W, Bellone CJ, Baldassare JJ, (1999) RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 274: 3396-3401.
44. Croft DR, Olson MF, (2006) The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 26: 4612-4627.
45. Joyce PL, Cox AD, (2003) Rac1 and Rac3 are targets for geranylgeranyltransferase-I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. Cancer Res 63: 7959-7967.